Novavax

Novavax

NVAX· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -16.4% in FY2025

John C. Jacobs is the CEO of Novavax and was paid $8.9M in FY2025 (Dec), up 74%.

Pay$100 in the stock at the end of FY22 → $65
CEO pay is from each Novavax proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives6

See all
  1. 1John C. JacobsFY2025
  2. 2Elaine O'HaraFY2025
  3. 3James P. KellyFY2025
  4. 4Mark J. Casey, J.D.FY2025
  5. 5Ruxandra Draghia-AkliFY2025
  6. 6John J. TrizzinoFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Novavax paid its 6 named executives $22.4M in total in FY2025 (Dec). CEO John C. Jacobs was paid $8.9M of that.

Name
John C. JacobsPresident and CEO
Elaine O'HaraEVP, Chief Strategy OfficerNot disclosed
James P. KellyEVP, Chief Financial Officer and Treasurer
Mark J. Casey, J.D.EVP, Chief Legal Officer and Corporate Secretary
Ruxandra Draghia-AkliM.D., Ph.D. Former EVP, Head of Research & DevelopmentNot disclosedNot disclosed
John J. TrizzinoFormer President and Chief Operating Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2025 (Dec) proxy of Novavax names 20 peer companies for pay. Among Novavax and these peers, CEO pay was 4th highest of 11 and total shareholder return was the lowest of 11.

4th highest of 11in Novavax and its pay peers, FY2025 (Dec) by CEO pay:

$4.8M$23.3M

11th highest of 11in Novavax and its pay peers, FY2025 (Dec) by total shareholder return:

$6$198

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • David MottChair · 4 yr on the boardIndependentCompensation (Chair), Research and Development—Paid as an executive
  • John C. JacobsDirector · 1 yr on the boardNot independent—Paid as an executive
  • John W. ShiverDirector · -1 yr on the boardIndependentResearch and Development—Paid as an executive

The board of the latest proxy (FY2024).

Activity

  1. Pay
    Novavax General counsel pay rose 165% to $2.8M. The stock fell 16% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Novavax CEO pay rose 74% to $8.9M. The stock fell 16% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Novavax CFO pay rose 63% to $3.0M. The stock fell 16% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Novavax EVP, Chief Strategy Officer pay rose 125% to $3.7M. The stock fell 16% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Novavax General counsel pay fell 31% to $1.1M. The stock rose 68% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Novavax President pay fell 13% to $1.6M. The stock rose 68% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Novavax President pay rose 189% to $3.1M. The stock fell 93% in FY2022 (Dec).
    DEF 14A
  8. Pay
    Novavax CEO pay fell 30% to $5.1M. The stock rose 68% in FY2024 (Dec).
    DEF 14A
  9. Pay
    Novavax CFO pay rose 22% to $1.8M. The stock rose 68% in FY2024 (Dec).
    DEF 14A
  10. Pay
    Novavax CFO pay fell 35% to $3.2M. The stock fell 93% in FY2022 (Dec).
    DEF 14A
  11. Pay
    Novavax Former President, Research & Development pay fell 20% to $1.6M. The stock rose 68% in FY2024 (Dec).
    DEF 14A
  12. Board
    John W. Shiver joined the board of Novavax. John W. Shiver sits on no other public board.
    3
  13. Pay
    Novavax President pay fell 54% to $3.8M. The stock fell 53% in FY2023 (Dec).
    DEF 14A
  14. Pay
    Novavax President pay rose 651% to $8.4M. The stock fell 93% in FY2022 (Dec).
    DEF 14A
  15. Pay
    Novavax President pay fell 39% to $1.9M. The stock fell 53% in FY2023 (Dec).
    DEF 14A
  16. Pay
    Novavax CFO pay fell 53% to $1.5M. The stock fell 53% in FY2023 (Dec).
    DEF 14A
  17. Board
    John C. Jacobs joined the board of Novavax. John C. Jacobs sits on no other public board.
    3

Filings6

See all
Proxy statementDEF 14AApr 27, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KFeb 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data